Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT07381816
Enrolling by invitation Not applicable

GastroFlow: Investigation of the Gastrointestinal Blood Flow in Patients With Postprandial Hypotension

NCT07381816 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2025-09-15
Last updated
2026-02-02

Condition(s) studied

Postprandial HypotensionHealthyBlood Flow

Investigational drug(s) / intervention(s)

MRI + GIPR antagonist (Tool)MRI + hangripSaline and oral glucose

MRI + GIPR antagonist (Tool): GIP(3-30)NH2 infusion, oral glucose during MRI scans

MRI + hangrip: Hangrip exercises, oral glucose during MRI scans

Saline and oral glucose: Saline infusion oral glucose during MRI scans

Study summary

This project will describe the mechanisms of action and the relative contributions of GIP to changes in gastrointestinal blood flow induced by oral glucose and endogenous GIP with the use of a receptor antagonists GIP(3-30)NH2 in patients with postprandial hypotension.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
Accepted
For the PPH group Inclusion Criteria: * Postprandial hypotension * Symptoms of postprandial hypotension Exclusion Criteria: * Treatment with drugs that cannot be paused for 12 hours * Metallic implants that does not tolerate MRI * Any other disease or dysfunction that may disturb blood flow to the gut * Intake of more than 14 units of alcohol per week or abuse of drugs * Blood vessels that are not feasible for measuring flow in the MRI scanner * Low blood percent * Decreased kidney function * Decreased liver function * Claustrophobia For the healthy group Inclusion Criteria: * Matched by age, gender and BMI Exclusion Criteria: * Postprandial hypotension * Metallic implants that does not tolerate MRI * Intake of more than 14 units of alcohol per week or abuse of drugs * Blood vessels that are not feasible for measuring flow in the MRI scanner * Low blood percent * Decreased kidney function * Decreased liver function * Claustrophobia * Autonomic dysfunction or other disease that cause changes in blood pressure during or after a meal * Intake of pharmaceutical products that influence the blood pressure

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Glostrup hospital Glostrup Municipality Denmark

More University of Copenhagen trials in Denmark

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07381816 on ClinicalTrials.gov ↗ ← All trials in Denmark